Biorepository Core B

生物样本库核心B

• 批准号: 10361544
• 负责人: CLAUDIO FIOCCHI
• 金额: $ 22.01万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10361544
• 关键词: Adipocytes; Area; Basic Science; Biology; Biopsy; Cancer Control; Cell Separation; Cells; Chronic; Classification; Clinic; Clinical; Clinical Data; Clinical Investigator; Clinical Laboratory Information Systems; Clinical Research; Colon Carcinoma; Constipation; Consultations; Consumption; Crohn' s disease; DNA; Data Analyses; Diagnosis; Digestive System Disorders; Diverticulosis; Elements; Epidemiology; Epithelial Cells; Esophagus; Experimental Designs; Familial Adenomatous Polyposis Syndrome; Feces; Flow Cytometry; Foundations; Funding; Gastrointestinal tract structure; Genealogy; Generations; Genetic; Genotype; Goals; Human; Human Resources; In Vitro; Individual; Inflammation; Institution; Institutional Review Boards; Intestinal Volvulus; Intestines; Large Intestine; Liver diseases; Logistics; Malignant Neoplasms; Malignant neoplasm of esophagus; Mesentery; Metabolism; Methods; Monitor; Operative Surgical Procedures; Organoids; Patients; Performance; Phenotype; Physicians; Process; Research; Research Activity; Research Institute; Research Personnel; Research Priority; Research Project Grants; Resources; Retrieval; Running; Sampling; Scientist; Serum; Services; Small Intestines; Specimen; Supervision; System; Time; Tissues; Training; Translating; Translational Research; Ulcerative Colitis; Universities; bench to bedside; biobank; cell type; community center; cost effective; cost effectiveness; design; experience; gastrointestinal; genomic platform; improved; member; monolayer; patient oriented research; research study; single cell analysis; success; synergism; translational study; tumorigenesis

BIOREPOSITORY CORE B PROJECT SUMMARY Dr. Claudio Fiocchi is Core Director. Dr. Florian Rieder serves as Associate Director, and Drs. Jean-Paul Achkar, Jennifer Ko and Amitabh Chak serve as Technical Directors. Goals of the Biorepository Core: The specific goals include: 1) Procure, process, and distribute tissue and cells from surgical specimens and biopsies, as well as serum, DNA and stools, from patients with gastrointestinal inflammation, cancer and controls for use in IRB-approved projects of DDRCC members; 2) Provide phenotypic, genotypic, clinical and demographic information of the biosamples; 3) Provide isolation, purification, culture and use of most types of gastrointestinal tract cells; 4) Advise, teach, and supervise investigators on principles, methods, analysis and experimental design; 5) Monitor Core services and continuously evaluate the needs of the DDRCC members to maximally benefit their research priorities, and 6) provide all above services in the most cost-effective and least time-consuming manner. Benefits of the Biorepository Core: During the first 4 years of funding, the objective evidence for the essential benefits of the Cleveland DDRCC Biorepository Core is the fact not a single investigator of the large DDRCC community has failed to receive the type, size or number of biospecimens, as well as the training and logistic support required for his/her studies. This success was achieved by the careful enactment of the specific goals. A new benefit of the Core is a state-of-the-art laboratory information system (LabVantage Solutions-LV), which tracks origin of samples, clinical information, genealogy of samples, and sample retrieval and distribution, and has connectivity to EPIC, Copath, Sunquest, etc. This new system greatly benefits Core users by assuring specimen quality, quick identification, diagnosis and delivery, and formal access to clinical data for interpretation of the experimental results. Finally, the Core has considerably expanded its technical services to include 1) generation of intestinal organoids, 2) organoid-derived epithelial cell monolayers, 3) isolation of mesenteric adipocytes, 4) single cell analysis (Fluidigm C1 and 10X Genomics platforms), 5) CyTOF and spectral flow cytometry systems, and 6) access to a large biobank of esophageal and colon cancer specimens. Overall, the Core benefits DDRCC members by providing unique and high quality biosamples and services.

生物座核B项目摘要 Claudio Fiocchi博士是核心主任。 Florian Rieder博士担任副主任和Drs。让·保罗 Achkar，Jennifer Ko和Amitabh Chak担任技术总监。 生物座核的目标：具体目标包括：1）采购，过程和分发组织和分发 胃肠道患者的手术标本和活检以及血清，DNA和粪便的细胞 炎症，癌症和对照在IRB批准的DDRCC成员的项目中； 2）提供表型， 生物样本的基因型，临床和人口统计信息； 3）提供隔离，纯化，文化和 使用大多数类型的胃肠道细胞； 4）建议，教和监督调查人员有关原则的建议， 方法，分析和实验设计； 5）监视核心服务并不断评估 DDRCC成员最大程度地使他们的研究优先事项受益，6）在 最具成本效益和最小耗时的方式。 生物座席核心的好处：在资金的头四年中，客观证据 克利夫兰DDRCC生物座位核心的基本好处是事实不是大型研究者 DDRCC社区未能获得生物测量的类型，大小或数量，以及培训和 他/她学习所需的后勤支持。通过仔细制定特定 目标。核心的新好处是最先进的实验室信息系统（LabVantage Solutions-LV）， 哪个跟踪样品的起源，临床信息，样本的家谱以及样本检索以及 分发，并且与Epic，Copath，Sunquest等具有连接性。这种新系统极大地使核心用户受益 通过确保标本质量，快速识别，诊断和交付以及对临床数据的正式访问 解释实验结果。最后，核心将其技术服务大大扩展到 包括1）产生肠道器官，2）类器官衍生的上皮细胞单层，3）分离 肠系膜脂肪细胞，4）单细胞分析（流体C1和10倍基因组学平台），5）cytof和cytof和 光谱流式细胞仪系统，以及6）进入大型食管和结肠癌标本的生物库。 总体而言，核心通过提供独特和高质量的生物样本和服务来使DDRCC成员受益。